Natalizumab
Natalizumab is a monoclonal antibody used to treat relapsing forms of multiple sclerosis (MS) and, in certain countries, moderate-to-severe Crohn’s disease in patients who have not responded adequately to other treatments. It works by binding to the α4-integrin protein on immune cells, reducing their movement across blood vessel walls into the central nervous system or intestinal tissues and thereby limiting inflammation. Natalizumab is administered as an intravenous infusion, with dosing and treatment duration determined by the approved indication and clinical protocol. Common side effects include headache, fatigue, joint pain, nausea, and infusion-related reactions. A serious but uncommon risk is progressive multifocal leukoencephalopathy (PML), a potentially life-threatening brain infection, particularly in patients with certain risk factors. Treatment requires specialist supervision, assessment of JC virus status, and regular monitoring for neurological symptoms, infections, and other adverse effects.
Natalizumab was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Natalizumab, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Natalizumab from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Natalizumab, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
